Dinutuximab (ch 14.18) in Osteosarcoma pt’s – AOST1421

  • Dinutuximab (ch 14.18) in Osteosarcoma pt’s – AOST1421

    Posted by Michele Ritter on September 26, 2016 at 12:03 pm

    Would anyone be willing to share their experience with a Osteosarcoma patient receiving Dinutuximab IV over 2 days for recurrent disease in the lungs that has been completely resected for patients that have been enrolled on study AOST1421? Are they tolerating Dinutux over 2 days? Any other issues or side effects seen that wasn’t seen in the Neuroblastoma patients? Would appreciate any input or any helpful tips or suggestions as we get ready to enroll our first Osteo patient to receive this therapy and start in a few weeks. Thanks so much!

    ——————————
    Michele Pope, PPCNP-BC,CPON,MSN
    Pediatric Nurse Practitioner
    Arnold Palmer Hospital for Children
    Orlando, FL
    United States
    ——————————

    Amy Forsythe replied 7 years, 6 months ago 2 Members · 1 Reply
  • 1 Reply
  • Amy Forsythe

    Member
    September 26, 2016 at 2:04 pm
    We’ve recently had an Osteo patient get the drug. He did fine. Same side effects as with Neuroblastoma. He’s already gotten a couple of courses of it. 

    Sent from my iPhone

    ——Original Message——

    Would anyone be willing to share their experience with a Osteosarcoma patient receiving Dinutuximab IV over 2 days for recurrent disease in the lungs that has been completely resected for patients that have been enrolled on study AOST1421? Are they tolerating Dinutux over 2 days? Any other issues or side effects seen that wasn’t seen in the Neuroblastoma patients? Would appreciate any input or any helpful tips or suggestions as we get ready to enroll our first Osteo patient to receive this therapy and start in a few weeks. Thanks so much!

    ——————————
    Michele Pope, PPCNP-BC,CPON,MSN
    Pediatric Nurse Practitioner
    Arnold Palmer Hospital for Children
    Orlando, FL
    United States
    ——————————

Log in to reply.